HealthAstraZeneca-Amgen asthma drug achieves 69% remission in esophageal disease trial

Amgen and AstraZeneca said on Tuesday that their asthma drug eased swallowing difficulties and led to remission in 69% of patients with a chronic inflammatory disorder affecting the esophagus.

drug trialesophageal diseaseAstraZenecaAmgen

RReuters★★☆☆☆2026-10-20 18:35Original